I am excited to be part of a great panel exploring the future of rheumatic disease treatments. Join me from 4:00 pm – 6:30 on Nov. 15 as I join Julie Di Paolo of Johnson & Johnson,?Joy Buie, Ph.D., MSCR, RN of Lupus Foundation of America, Inc., and Aagam Shah, PhD of Sands Capital. Coinciding with the American College of Rheumatology Annual Meeting, this will be a great opportunity to connect with national and regional thought leaders at the nearby by the beautiful Venable LLC building. Want to network and join the conversation on bispecifics, novel oral therapies, and more??RSVP at https://lnkd.in/gKf_iumQ.
SecondWave Systems, Inc.
医疗设备制造业
Minneapolis，MN 605 位关注者
Developing a novel, ultrasound-based wearable neuromodulation platform
关于我们
SecondWave Systems is a pioneer in the emerging field of bio-ultrasonic medicine. The company is developing a first-of-its-kind noninvasive, wearable ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening disease.
- 网站
-
https://www.secondwaveUS.com
SecondWave Systems, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Minneapolis，MN
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
US，MN，Minneapolis
SecondWave Systems, Inc.员工
-
Hsin-Lei (Layla) Huang
Founder at VasoCollar 凡克生醫科技股份有限公司
-
Albert You
Director of Engineering @ SecondWave Systems, Inc. | PhD in Bioengineering @ UC Berkeley
-
John Basile
Senior Research and Development Engineer at SecondWave Systems, Inc.
-
Daniel Zachs
Director of Clinical Research at SecondWave Systems, Inc.
动态
-
Welcome! SecondWave Systems, Inc. has joined Fogarty Innovation’s company accelerator program (CAP). Led by founders Anuj Bhardwaj, Jeff Heyman, and Hubert Lim, SecondWave is treating rheumatoid arthritis with a wearable noninvasive device using ultrasonic immunomodulation. The company has completed the key technology that powers its device and demonstrated positive clinical results showing a reduction in disease activity for both moderate and severe RA patients. SecondWave has received funding totaling over $15 million to date from several U.S. government agencies and has worked with the University of Minnesota and other key partners to develop multiple generations of its wearable ultrasound device. During their time at Fogarty, the SecondWave team will focus on planning and executing their upcoming clinical study in rheumatoid arthritis. Learn more: https://lnkd.in/gQiaEBAT
-
-
Thank you BiotechTV and JLABS for giving our CEO Anuj Bhardwaj the opportunity to share our story yesterday.
???????? ????????: SecondWave Systems, Inc. is using low intensity ultrasound to treat inflammatory conditions like RA. Co-Founder & CEO Anuj Bhardwaj describes the device Second Wave has developed and how it is designed to hit the spleen with ultrasound, thus modulating the immune system. The idea could be used in other conditions like long covid or oncology as well. Full video: https://lnkd.in/gzBbxXeZ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh
-
Congratulations to the Setpoint team! This is a big win for patients suffering from rheumatoid arthritis, and validates that activation of the vagus nerve and converging neural pathways through the spleen works to treat inflammatory disease.
Major news: We are thrilled to announce that the RESET-RA study has successfully met its primary endpoint!? ???? This morning, we announced positive topline results from this landmark clinical study highlighting that neuroimmune modulation using the SetPoint System demonstrates a clinical benefit in adults living with moderate-to-severe rheumatoid arthritis (RA). “We are thrilled with these results from the RESET-RA study as they highlight the potential of the SetPoint System for providing rheumatologists and their patients a safe and effective treatment alternative to current RA therapies,” said Murthy Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. “As next steps, we look forward to submitting the data for presentation at upcoming rheumatology and neurosurgical medical meetings and completing our premarket approval submission to the FDA.” Read the full announcement from today’s release: https://lnkd.in/eizkT-4t #TheSetPointAdvantage #RheumatoidArthritis #RA This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.
-
We are thrilled to announce completion of a first-in-human clinical study in rheumatoid arthritis patients, demonstrating a significant reduction in disease activity with our novel focused ultrasound technology. https://lnkd.in/eyBEsTVE
SecondWave Systems Demonstrates Reduction in Disease Activity in Clinical Study Evaluating Novel Ultrasound-Based Anti-Inflammatory Therapy in Rheumatoid Arthritis
businesswire.com
-
Today, we're excited to welcome Paul Peter Tak, MD PhD FMedSci as a new advisory board member and announce additional funding to advance our focused ultrasound technology platform. https://lnkd.in/gwW68dG9
SecondWave Systems Announces Professor Paul Peter Tak as New Advisory Board Member and Secures $3M Additional Financing to Accelerate Development of Novel Ultrasound-Based Anti-Inflammatory Therapy
businesswire.com
-
SecondWave CEO Anuj Bhardwaj will be speaking at the Bioelectric Medicine Development Summit running June 4-6 in Boston! You can find out more information about this session or the whole forum by downloading the full event guide here https://ter.li/7cjcpq. We hope to see you there!
-
-
Congratulations to SecondWave’s Chief Scientific Officer, Dr. Hubert Lim, on his new appointment as the Director of the Earl E. Bakken Medical Device Center at the University of Minnesota! The SecondWave team is excited for Dr. Lim’s vision in expanding the Bakken Center to serve as the bridge between the growing #medtech industry in the Twin Cities with the extensive resources and innovations at the University of Minnesota. Dr. Lim and the Bakken Center, together with partners of the Minnesota MedTech 3.0 initiative, will also help support start-up companies across Minnesota - companies like SecondWave who have successfully grown through the Twin Cities ecosystem.
We are #UMNProud of biomedical engineering professor, Dr. Hubert Lim, who was named the next Director of the Earl E. Bakken Medical Device Center at the University of Minnesota. Read more about his new role at https://lnkd.in/gYETNWA8 Earl E. Bakken Medical Devices Center, UMN // Institute for Engineering in Medicine, University of Minnesota // University of Minnesota // University of Minnesota Department of Biomedical Engineering
CSE Professor Hubert Lim named director of Bakken Medical Devices Center
cse.umn.edu
-
?? Are you an expert in Bioelectric Medicine & Neuromodulation? ?? Then the Bioelectric Medicine Development Summit is your must-attend meeting! Our expert speaker faculty includes Alexander Yeh, Anuj Bhardwaj, Bryan McLaughlin, David Miller, Greg Alden, Imran Eba, Josh Boggs, Katherine Neuenfeldt, Kate Rosenbluth, Kathryn Nichol, Keith Warner, Ken Mariash, Mary McNamara-Cullinane, Ralph Kern, Raymond W. Cohen, Shyamy Sastry, Steven McQuillan, William Phillips, Vivek Pinto, PhD, MBA Candidate. Dive deeper and get crucial insights into: ? The Venture Community & Funding for Neurostimulation Start-Ups ? An Overview of CDRH & Regulatory Pathways to Provide Novel Neuromodulation & Physical Medicine Devices to Patients ? A Step by Step Approach to Position Bioelectric for Optimum Fundraising ? The Benefits of Using Bioelectric Medicine Over Conventional Procedures to Reduce Patient Resistance Interested in learning more? BRAND NEW Event Guide here: https://ter.li/ijgj5d
? JUST LAUNCHED ? We're thrilled to announce the launch of?Bioelectric Medicine Development Summit?(Boston | June 4-6), the only industry-led forum for experts developing medical grade neurostimulation devices. The summit is dedicated to bringing bioelectric medicine experts together to share cutting-edge insights in streamlining neuromodulation device approval from proof of concept to regulatory strategy. Prepare to be inspired by an incredible line-up of experts in the space, including: Alexander Yeh, Kathryn Nichol, Ken Mariash, Raymond W. Cohen, Vivek Pinto, PhD, MBA Candidate, Greg Alden, Imran Eba, Kate Rosenbluth, Keith Warner and many more! This is your opportunity to be at the forefront of a transformative industry with?80+ neurostimulation experts?from?LivaNova, FDA, Boomerang Medical,?Axonics, Inc.,?Neuspera Medical Inc.,?Sinaptica Therapeutics,?Saluda Medical,?SPR Therapeutics, Inc.?and many more to discover novel strategies in obtaining funding, shortening clinical trials, approaching regulatory bodies, and overcoming reimbursement barriers. Be the first to see the brand-new Event Guide with our star speaker faculty?here: https://ter.li/ijgj5d
-